ONCOCheck: Next Generation Sequencing for Oncology Diagnosis

14 Jun , 2017 Cover,[:it]News da Microgenomics[:en]News from Microgenomics[:]

ONCOCheck: Next Generation Sequencing for Oncology Diagnosis

Microgenomics laboratory announces the introduction of a new line of NGS genetic tests dedicated to oncology diagnostics.

Every day in Italy will find nearly 1,000 new cases of cancer. In recent years the percentage of healing have improved thanks to increased adhesion of the population in screening protocols and early diagnosis. A significant proportion of cancers is hereditary (from 8% to 20% depending on the type) and genomic mutations can be passed from one generation to the next.

Our genetic tests identify mutations that predispose the development of some hereditary cancers and they also define the genetic causes of cancer in people who have already expressed pathology.

Discover our tests!

ONCOCheck Hereditary Cancer-Tumori Ereditari

Microgenomics laboratory genetic test analises 27 genes associated with the most common hereditary tumors, such as breast and ovarian cancer, colon cancer, pancreas cancer and many more.


Molecular analysis for the identification of SNVs and CNAs in 26 frequently mutated genes in solid tumors.


This test targets mutations in 54 genes (tumor suppressor genes and oncogenic hotspots) involved in different onco-hematological disease.

For more information click on each test ‘s icon or download the dedicated flyer!

For further information about collection and shipment of samples, and to receive analysis application forms or other clarifications contact us.


, , , , , , , , ,